Outstanding manufacturing performance: Steve Walls, Dean Murray (Ward Hadaway), Gary Reid (Aesica Pharmaceutical) & Iain Wright (NEPIC)
Over the last 3 years, the Aesica Pharmaceutical facility in Cramlington has undergone a significant programme of change, leading to an operation that is driving step change performance improvement in terms of EHS, customer service, quality and financial operating performance. This change in approach and outlook has seen the site win new long term contracts, increasing site turnover by over 30%, whilst improving all aspects of its operation.
Acquired in 2014 by LSE listed company Consort Medical, the Cramlington facility had to change to deliver long term shareholder growth, increasing sales and profitability whilst mitigating risks for its shareholders. Through the active engagement of people throughout the organisation in the site’s Operational Excellence drive, the results of this programme of change are clear to see.
At the forefront is the organisation’s commitment to drive the site’s EHS performance, resulting in significant milestones including 1,000,000 hours worked since last lost time accident, 80% reduction in chemical emissions on volume production train and full electricity and steam conversion to the new CHP facility. Quality and delivery performance have seen improvements also. The firm achieved a 70% reduction in open quality deviations, 95% product right first time and 96% documentation right first time. Production batches manufactured increased by 30%, train days by 15% and time, in full, delivery performance is exceeding 98%. Furthermore, shop floor driven improvements have reduced bottlenecking and increased product yield.
Across all aspects of the business, the Aesica Pharmaceutical Cramlington site has achieved significant results that will help drive long term growth, new business and the site’s future for many years to come. A very worthy winner of the 2018 Manufacturer of the Year Award.
<< Back to Awards Home Page